PL2999485T3 - Kompozycja immunogenna peptydów gastrynowych - Google Patents
Kompozycja immunogenna peptydów gastrynowychInfo
- Publication number
- PL2999485T3 PL2999485T3 PL14724102T PL14724102T PL2999485T3 PL 2999485 T3 PL2999485 T3 PL 2999485T3 PL 14724102 T PL14724102 T PL 14724102T PL 14724102 T PL14724102 T PL 14724102T PL 2999485 T3 PL2999485 T3 PL 2999485T3
- Authority
- PL
- Poland
- Prior art keywords
- immunogenic composition
- gastrin peptide
- peptide immunogenic
- gastrin
- composition
- Prior art date
Links
- 108010052343 Gastrins Proteins 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001144—Hormones, e.g. calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13168565 | 2013-05-21 | ||
| PCT/EP2014/060088 WO2014187743A1 (en) | 2013-05-21 | 2014-05-16 | Gastrin peptide immunogenic composition |
| EP14724102.0A EP2999485B1 (en) | 2013-05-21 | 2014-05-16 | Gastrin peptide immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2999485T3 true PL2999485T3 (pl) | 2018-07-31 |
Family
ID=48446168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14724102T PL2999485T3 (pl) | 2013-05-21 | 2014-05-16 | Kompozycja immunogenna peptydów gastrynowych |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10328134B2 (pl) |
| EP (1) | EP2999485B1 (pl) |
| JP (1) | JP6395816B2 (pl) |
| CN (1) | CN105407919B (pl) |
| AU (1) | AU2014270595B2 (pl) |
| BR (1) | BR112015028429A2 (pl) |
| CA (1) | CA2912736C (pl) |
| ES (1) | ES2665780T3 (pl) |
| HU (1) | HUE037252T2 (pl) |
| PL (1) | PL2999485T3 (pl) |
| PT (1) | PT2999485T (pl) |
| RU (1) | RU2664197C2 (pl) |
| WO (1) | WO2014187743A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11154599B2 (en) | 2015-05-18 | 2021-10-26 | Oncoqr Ml Gmbh | Her2/neu immunogenic composition |
| US10590180B2 (en) | 2015-06-19 | 2020-03-17 | National University Corporation Shizuoka University | Immune function development promoter and growth promoter |
| JP6934860B2 (ja) * | 2015-09-01 | 2021-09-15 | オンコクール・エムエル・ゲーエムベーハー | コイルドコイルコネクタ |
| AU2018283284B2 (en) | 2017-06-15 | 2024-05-16 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| CN111150842B (zh) * | 2019-12-31 | 2023-09-05 | 优锐生物医药科技(深圳)有限公司 | 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用 |
| WO2022155320A1 (en) * | 2021-01-13 | 2022-07-21 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| CN118165123B (zh) * | 2024-05-11 | 2024-08-09 | 北京春雷杰创生物科技有限公司 | 蛋白复合物及其制备方法 |
| CN119375496B (zh) * | 2024-12-27 | 2025-03-28 | 美康生物科技股份有限公司 | 一种肿瘤标志物多项质控品 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2063912T3 (es) * | 1989-01-24 | 1995-01-16 | Aphton Corp | Composiciones inmunogenicas frente a peptidos de gastrina. |
| US5023077A (en) * | 1989-01-24 | 1991-06-11 | Aphton Corporation | Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease |
| US5468494A (en) | 1993-11-12 | 1995-11-21 | Aphton Corp. | Immunogenic compositions against human gastrin 17 |
| GB9516760D0 (en) | 1995-08-16 | 1995-10-18 | Sandoz Ltd | Organic compounds |
| PT889735E (pt) * | 1996-02-08 | 2011-07-19 | Cancer Advances Inc | Métodos imunológicos para o tratamento do cancro gastrointestinal |
| WO2005095459A2 (en) * | 2004-03-29 | 2005-10-13 | Receptor Biologix, Inc. | Monoclonal antibodies to gastrin hormone |
| US7574259B1 (en) * | 2004-11-12 | 2009-08-11 | Pacesetter, Inc. | Capture threshold and lead condition analysis |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| PL2046334T3 (pl) * | 2006-07-25 | 2015-02-27 | Vecta Ltd | Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI |
| US8580274B2 (en) * | 2009-02-10 | 2013-11-12 | University Of The Ryukyus | Drug transporter, and adjuvant and vaccine each utilizing same |
| WO2014009209A2 (en) | 2012-07-13 | 2014-01-16 | S-Target Therapeutics Gmbh | Immunoregulatory vaccine |
| EP3297547B1 (en) | 2015-05-21 | 2023-11-01 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Device for injection, photoactivation and solidifaction of liquid embolic material in the vascular system or other organic cavities |
-
2014
- 2014-05-16 CA CA2912736A patent/CA2912736C/en active Active
- 2014-05-16 PL PL14724102T patent/PL2999485T3/pl unknown
- 2014-05-16 CN CN201480032978.4A patent/CN105407919B/zh active Active
- 2014-05-16 JP JP2016514341A patent/JP6395816B2/ja active Active
- 2014-05-16 BR BR112015028429A patent/BR112015028429A2/pt not_active IP Right Cessation
- 2014-05-16 RU RU2015154795A patent/RU2664197C2/ru active
- 2014-05-16 ES ES14724102.0T patent/ES2665780T3/es active Active
- 2014-05-16 AU AU2014270595A patent/AU2014270595B2/en active Active
- 2014-05-16 PT PT147241020T patent/PT2999485T/pt unknown
- 2014-05-16 US US14/892,973 patent/US10328134B2/en active Active
- 2014-05-16 HU HUE14724102A patent/HUE037252T2/hu unknown
- 2014-05-16 EP EP14724102.0A patent/EP2999485B1/en active Active
- 2014-05-16 WO PCT/EP2014/060088 patent/WO2014187743A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014270595A1 (en) | 2015-11-12 |
| RU2015154795A (ru) | 2017-06-26 |
| RU2664197C2 (ru) | 2018-08-15 |
| AU2014270595B2 (en) | 2019-04-04 |
| CA2912736A1 (en) | 2014-11-27 |
| JP6395816B2 (ja) | 2018-09-26 |
| JP2016523837A (ja) | 2016-08-12 |
| EP2999485A1 (en) | 2016-03-30 |
| CN105407919B (zh) | 2019-08-06 |
| HUE037252T2 (hu) | 2018-08-28 |
| EP2999485B1 (en) | 2018-01-31 |
| WO2014187743A1 (en) | 2014-11-27 |
| CA2912736C (en) | 2021-09-07 |
| US10328134B2 (en) | 2019-06-25 |
| US20160129096A1 (en) | 2016-05-12 |
| CN105407919A (zh) | 2016-03-16 |
| ES2665780T3 (es) | 2018-04-27 |
| PT2999485T (pt) | 2018-04-30 |
| BR112015028429A2 (pt) | 2017-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279395A (en) | A vaccine | |
| IL242005B (en) | A peptide compound | |
| SG11201507883SA (en) | Wt1-antigen peptide conjugate vaccine | |
| ZA201505966B (en) | Peptides and compositions | |
| PT2999485T (pt) | Composição imunogénica do peptido gastrina | |
| GB201314411D0 (en) | Peptide conjugates | |
| ZA201600729B (en) | Peptides | |
| GB201301457D0 (en) | Freeze-dried composition | |
| IL244986A0 (en) | Formulation for gonadotropins | |
| ZA201504986B (en) | Peptide | |
| PT3061771T (pt) | Novo péptido unido a quatro epitopos ctl | |
| ZA201504987B (en) | Peptide | |
| GB201322948D0 (en) | Improved formulation | |
| GB201315130D0 (en) | Peptides | |
| IL244956A0 (en) | New peptide compositions | |
| GB201316660D0 (en) | Peptides | |
| GB201300381D0 (en) | Peptides | |
| GB201305465D0 (en) | Novel peptides |